Arrowhead Pharmaceuticals/$ARWR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
- Ticker
- $ARWR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 711
- Headquarters
- Pasadena, United States
- Website
- arrowheadpharma.com
ARWR Metrics
BasicAdvanced
$6.7B
-
-$2.28
1.29
-
Price and volume
Market cap
$6.7B
Beta
1.29
52-week high
$95.49
52-week low
$37.06
Average daily volume
2M
Financial strength
Current ratio
5.899
Quick ratio
5.706
Long term debt to equity
2.856
Total debt to equity
2.96
Interest coverage (TTM)
-2.45%
Profitability
EBITDA (TTM)
-200.635
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-47.79%
Operating margin (TTM)
-33.82%
Effective tax rate (TTM)
-7.95%
Revenue per employee (TTM)
$940,000
Management effectiveness
Return on assets (TTM)
-8.10%
Return on equity (TTM)
-55.21%
Valuation
Price to revenue (TTM)
9.893
Price to book
14.29
Price to tangible book (TTM)
14.47
Price to free cash flow (TTM)
-88.177
Free cash flow yield (TTM)
-1.13%
Free cash flow per share (TTM)
-0.535
Growth
Revenue change (TTM)
16.85%
Earnings per share change (TTM)
100.62%
3-year revenue growth (CAGR)
37.74%
10-year revenue growth (CAGR)
128.73%
3-year earnings per share growth (CAGR)
10.23%
10-year earnings per share growth (CAGR)
4.93%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
Analyst projections of the future price of Arrowhead Pharmaceuticals stock.
Bulls say / Bears say
In two Phase 3 trials, plozasiran cut triglycerides by 79% and 81% and reduced acute pancreatitis events by 78% versus placebo. That gives Arrowhead strong evidence to seek a much broader severe hypertriglyceridaemia label. (Arrowhead Pharmaceuticals Inc.)
The FDA accepted plozasiran into its STAR pilot, which offers a six-month priority review and may allow an earlier decision on the planned severe hypertriglyceridaemia label expansion. Arrowhead says it remains on track to file by the end of 2026. (Arrowhead Pharmaceuticals, Inc.)
ARO-MAPT reduced a brain-related tau biomarker in healthy volunteers by a mean of up to 73%, with reductions lasting 90 days after the final dose. This is early evidence that Arrowhead’s RNAi approach can reach the brain, though benefit for Alzheimer’s patients remains unproven. (Arrowhead Pharmaceuticals Inc.)
REDEMPLO sales were about $2.4 million in fiscal Q3, so the commercial launch is still small despite prescriptions roughly doubling. Growth and wider uptake remain important tests of the company’s commercial case. (Investing.com)
Arrowhead reported a $194.3 million net loss in fiscal Q3, as operating expenses of $245.3 million far exceeded revenue of $75.3 million. Continued high research and commercial spending could weigh on returns even with substantial cash and investments. (U.S. Securities and Exchange Commission)
Ionis has an ongoing patent infringement lawsuit over Arrowhead’s planned plozasiran commercialisation and is seeking damages. An adverse outcome could complicate the launch or add costs. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
MarketBeat14 hours ago
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
Business Wire6 days ago
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
Business Wire1 week ago
Funds containing ARWR
Fund name | Fund size | $ARWR weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.6B | 0.67% |
iShares Healthcare Innovation$HEAL | $1.6B | 0.67% |
iShares Healthcare Innovation€2B78 | $1.6B | 0.67% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.44% |
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.44% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.